SOURCE: Lipid Sciences, Inc.

April 10, 2006 08:30 ET

Lipid Sciences Participates in CRT 2006 Symposium

HDL Selective Delipidation Effectiveness Data Highlighted

PLEASANTON, CA -- (MARKET WIRE) -- April 10, 2006 -- Lipid Sciences, Inc. (NASDAQ: LIPD) today announced that the Company had participated in the recent Cardiovascular Revascularization Therapies: CRT 2006 Symposium held in Washington, D.C., April 3-6, 2006. CRT 2006 is an international multi-modular symposium that covers a variety of evidence based medical disciplines in the field of cardiovascular medicine and intervention. A renowned faculty of experts from around the world who are leaders in their field discussed mechanistic issues, clinical controversies and current experiences both in animal models and in clinical patient treatment settings.

Lipid Sciences sponsored an Evening Satellite Symposium, "HDL: New Frontiers in the Treatment of Cardiovascular Disease." Dr. H. Bryan Brewer, Jr., Lipid Sciences' Chief Scientific Director, and the Director of Lipoprotein and Atherosclerosis Research at the Cardiovascular Research Institute, Washington Hospital Center, discussed "How HDL Protects Against Cardiovascular Disease." In his presentation, Dr. Brewer noted that HDL therapy is clearly becoming the new frontier in the treatment of cardiovascular disease. He stated that, even with the best, current cardiovascular therapies, there is still a 22% recurrence of acute coronary events after only two years. That means more than one out of five people experiencing an acute coronary syndrome today will suffer a second event within 24 months. There is obviously an important role for HDL therapy, such as Lipid Sciences' HDL Selective Delipidation therapy, to fill that unmet clinical need.

Dr. Ron Waksman, Associate Director, Division of Cardiology, Washington Hospital Center, and Principal Investigator of Lipid Sciences' upcoming human clinical trial, discussed "Autologous Delipidated HDL Infusions: A New Approach for the Treatment of the Acute Coronary Syndrome." Dr. Waksman provided perspective on Lipid Sciences' upcoming human clinical trial of the Company's Plasma Delipidation System-2 (PDS-2). He began his presentation by announcing that a discrete lesion analysis of Intravascular Ultrasound (IVUS) data collected during a pre-clinical animal study demonstrated a statistically significant 6.59% reduction of total atheroma volume (p=0.029) associated with the discrete atherosclerotic lesions in the monkey aortas following a regimen of 12 plasma delipidation/re-infusions. The treatment process was well tolerated by the animals. This animal study was conducted at Wake Forest Baptist Medical Center in a population of 12 African Green monkeys -- a widely accepted model for human atherosclerosis. The data from the study were included in the Lipid Sciences' application, which received conditional approval earlier this year by the FDA to support the initiation of a human clinical trial for the PDS-2 system. Volcano Therapeutics, Inc. collaborated with Lipid Sciences by providing its latest generation IVUS system to evaluate the effects of HDL Therapy on this unique animal population.

Dr. Waksman also noted that the analysis of the IVUS data for the upcoming human trial will be conducted at two IVUS core laboratories: at the Cardiovascular Research Institute at the Washington Hospital Center by Dr. Neil J. Weissman, Director of the Cardiac Ultrasound and Ultrasound Core Laboratories, and at Stanford University Medical Center by Dr. Peter J. Fitzgerald, Director of the Center for Research in Cardiovascular Interventions and the Cardiovascular Core Analysis Laboratory.

Dr. Prediman K. Shah, Director of the Division of Cardiology and the Atherosclerosis Research Center at the Cedars-Sinai Medical Center, discussed "ApoA-I Milano: Evolution from a Genetic Mutation to a Therapeutic Target for Cardiovascular Disease." Dr. Shah detailed the highlights of the landmark ApoA-1 Milano study that was conducted by Esperion Therapeutics. He also validated the role of HDL therapy as a new treatment strategy for patients with Acute Coronary Syndrome.

Dr. S. Lewis Meyer, President and Chief Executive Officer of Lipid Sciences, commented, "We are very pleased to have the opportunity to participate in CRT 2006 and to have had our HDL Selective Delipidation System introduced to this audience of medical experts and clinicians. Our comprehensive strategy for HDL Therapy was well received by those in attendance. We now look forward to the imminent initiation of a human clinical trial of our Plasma Delipidation System-2 at the Washington Hospital Center. We expect to report on the progress of our trial throughout 2006 and detail the results of the study at CRT 2007."

Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company's HDL Therapy platform (HDL Selective Delipidation and HDL mimetic peptides) is aimed at developing treatments for the reversal of atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy platform is focused on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by application of Lipid Sciences' proprietary delipidation technology. The Company believes that removing the virus' protective lipid coating enhances the processing and presentation of viral proteins to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by this technology include HIV, Hepatitis B and Hepatitis C, West Nile, SARS and influenza.

Forward-Looking Statements: This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers are referred to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: Our inability to obtain adequate funds; our technology not proving to be safe or effective; our inability to obtain regulatory approval for our technology, which is only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International B.V.; our reliance on collaborations with strategic partners and consultants; competition in our industry, including the development of new products by others that may provide alternative or better therapies; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; acceptance of our potential products by healthcare providers and patients; and our dependence on key personnel.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov. Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.

Press releases for Lipid Sciences, Inc. are available on our website: www.lipidsciences.com. If you would like to receive our press releases via email, please contact: info @lipidsciences.com.

Contact Information

  • FOR FURTHER INFORMATION CONTACT:
    Deborah S. Lorenz
    Vice President, Investor Relations and Corporate Communications
    Lipid Sciences, Inc.
    925-249-4031
    Email Contact

    Wolfe Axelrod Weinberger Associates, LLC
    Donald C. Weinberger
    Email Contact
    Media:
    Alisa Steinberg
    Email Contact
    212-370-4500